Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
REVIEW
Meng Huang, Zhiwen Zhao, Lihua Yang
BACKGROUND: Recently, increasing data have suggested that the lncRNA small nucleolar RNA host genes (SNHGs) were aberrantly expressed in hepatocellular carcinoma (HCC), but the association between the prognosis of HCC and their expression remained unclear. The purpose of this meta-analysis was to determine the prognostic significance of lncRNA SNHGs in HCC. METHODS: We systematically searched Embase, Web of Science, PubMed, and Cochrane Library for eligible articles published up to February 2024...
April 2024: Cancer Medicine
#2
JOURNAL ARTICLE
Liu Zhang, Yi-Jiang Zhu, Xue-Qing Wang, Rui-Feng Wang, Li Dong, Liang Yin, Wei-Fu Lv, De-Lei Cheng, Chun-Ze Zhou
BACKGROUND AND AIMS: Performing a Transjugular intrahepatic portal system shunt (TIPS) in patients with portal vein cavernous transformation (CTPV) poses significant challenges. As an alternative, transjugular extrahepatic portal vein shunt (TEPS) may offer a potential solution for these patients. Nonetheless, the effectiveness and safety of TEPS remain uncertain. This case series study aimed to evaluate the efficacy and safety of TEPS in treating patients with CTPV portal hypertension complications...
April 9, 2024: Hepatology International
#3
JOURNAL ARTICLE
Kisako Fujiwara, Takayuki Kondo, Kentaro Fujimoto, Sae Yumita, Keita Ogawa, Takamasa Ishino, Miyuki Nakagawa, Terunao Iwanaga, Satoshi Tsuchiya, Keisuke Koroki, Hiroaki Kanzaki, Masanori Inoue, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Sadahisa Ogasawara, Shingo Nakamoto, Tetsuhiro Chiba, Jun Koizumi, Jun Kato, Naoya Kato
BACKGROUND: During systemic therapy, the management of portal hypertension (PH)-related complications is vital. This study aimed to clarify factors associated with the incidence and exacerbation of PH-related complications, including the usefulness of contrast-enhanced computed tomography (CECT) in the management of PH-related complications during systemic therapy. METHODS: A total of 669 patients who received systemic therapy as first-line treatment (443 patients for sorafenib, 131 for lenvatinib, and 90 for atezolizumab/bevacizumab [ATZ/BEV]) were enrolled in this retrospective study...
April 7, 2024: Journal of Gastroenterology
#4
JOURNAL ARTICLE
Christian Bracco, Marta Gallarate, Marco Badinella Martini, Corrado Magnino, Salvatore D'Agnano, Roberta Canta, Giulia Racca, Remo Melchio, Cristina Serraino, Valentina Polla Mattiot, Giovanni Gollè, Luigi Fenoglio
BACKGROUND: Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the second leading cause of cancer deaths worldwide. It is often diagnosed at an advanced stage and therefore its prognosis remains poor with a low 5-year survival rate. HCC patients have increasingly complex and constantly changing characteristics, thus up-to-date and comprehensive data are fundamental. AIM: To analyze the epidemiology and main clinical characteristics of HCC patients in a referral center hospital in the northwest of Italy between 2010 and 2019...
March 15, 2024: World Journal of Gastrointestinal Oncology
#5
JOURNAL ARTICLE
Maria Satya Paramitha, Dekta Filantropi Esa, Ni Made Hustrini, Nadia Ayu Mulansari, Irsan Hasan, Agnes Stephanie Harahap
Continuously holding its position as the sixth most common cause of cancer and the third leading cause of cancer death, globally, Hepatocellular Carcinoma (HCC) remains as a healthcare priority. Production of various substances may result into systemic or metabolic complications, often known as paraneoplastic phenomena of HCC. A 56-year-old male with history of untreated chronic hepatitis B arrived with generalized weakness and intermittent headache in the last two days prior to admission. Laboratory findings demonstrated elevated hemoglobin (20...
January 2024: Acta Medica Indonesiana
#6
JOURNAL ARTICLE
Brian I Carr, Harika Bag, Volkan Ince, Burak Isik, Adil Baskiran, Sezai Yilmaz
BACKGROUND AND AIM: Patients with hepatocellular carcinoma (HCC) are managed in various hospital departments, which complicates the assessment of the overall picture. In our large liver transplant institute, we evaluate all HCC patients in a weekly multi-disciplinary liver tumor board, and their data are prospectively collected in an institutional HCC database to evaluate HCC causes, tumor features, treatments, and survival. MATERIALS AND METHODS: Baseline data for patients (n=1322) were prospectively recorded, including hepatitis status, routine clinical serum parameters, radiological assessment of maximum tumor diameter (MTD), tumor number, presence of macroscopic portal vein thrombosis (PVT), and serum alpha-fetoprotein (AFP) levels...
2024: Hepatol Forum
#7
Teresa Fraga, Nuno Bonito
Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is an aggressive hepatic cancer that has characteristics of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). For resectable disease, liver resection is the preferred first treatment option. As for the advanced or metastatic setting, and due to its rarity, there is still no consensus on which is the optimal systemic treatment. As such, regimens used in both HCC and CC have often been used as first-line treatment options. We report a case of a male patient in his 50s, diagnosed with a cHCC-CC with lymph node and adrenal metastasis, with an extensive portal vein tumour thrombosis, that started treatment with a multikinase inhibitor - lenvatinib...
February 2024: Curēus
#8
John Hang Leung, Shyh-Yau Wang, Henry W C Leung, Agnes L F Chan
BACKGROUND: Portal vein tumor thrombus (PVTT) is a common complication and an obstacle to treatment, with a high recurrence rate and poor prognosis. There is still no global consensus or standard guidelines on the management of hepatocellular carcinoma (HCC) with PVTT. Increasing evidence suggests that more aggressive treatment modalities, including transarterial chemoembolization, radiotherapy, targeted therapy, and various combination therapies, may improve the prognosis and prolong the survival of advanced hepatocellular carcinoma (aHCC) patients with PVTT...
2024: Frontiers in Oncology
#9
Sania Ajmal, Srujan Edupuganti, Adiraj Singh
Cholangiocarcinoma (CCA) refers to malignancies of the bile ducts that arise in the intrahepatic, perihilar, or distal (extrahepatic) biliary tree, excluding the gallbladder and ampulla of Vater. Although rare, the majority of these cancers are locally advanced at presentation, making them extremely fatal. We present a case of a 65-year-old man who came in for abdominal pain and ascites and was found to have portal vein thrombosis. Initial imaging showed a hepatic lesion, raising suspicion of a hepatic malignancy...
January 2024: Curēus
#10
JOURNAL ARTICLE
Ahmed M Badheeb, Mohammed K Al Sedran, Faisal Ahmed, Ibrahim K Al Sidran, Mohammed H Al Qurayshah, Abdullah Abu Bakar, Hamoud Y Obied, Islam A Seada, Abdelaziz Aman, Mohamed Badheeb
Background Hepatocellular carcinoma (HCC) represents the most common primary liver malignancy, with a high fatality rate. Relatively, Saudi Arabia has a high incidence of HCC, which is detected in later stages with a poor prognosis. This study aims to investigate the patterns, outcomes, and mortality predictors of HCC in Saudi Arabia. Method A retrospective study from April 2018 to June 2022 included patients with HCC who were diagnosed and managed at the Najran Oncology Center, Saudi Arabia. Through our cancer registry, the patients' clinical, laboratory, radiological, and survival profiles were extracted and analyzed to assess factors associated with mortality using a univariate analysis...
January 2024: Curēus
#11
JOURNAL ARTICLE
Edo Dongelmans, Nicole Erler, Rene Adam, Silvio Nadalin, Vincent Karam, Sezai Yilmaz, Claire Kelly, Jacques Pirenne, Koray Acarli, Michael Allison, Abdul Hakeem, Dhakshinamoorthy Vijayanand, Dzmitry Fedaruk, Oleg Rummo, Murat Kilic, Arno Nordin, Lutz Fischer, Alessandro Parente, Darius Mirza, William Bennet, Yaman Tokat, Francois Faitot, Barbara B Antonelli, Gabriela Berlakovich, David Patch, Frederik Berrevoet, Marija Ribnikar, Theophile Gerster, Eric Savier, Salvatore Gruttadauria, Bo-Göran Ericzon, Andrés Valdivieso, Valentin Cuervas-Mons, Baltasar Perez Saborido, Roland S Croner, Luciano De Carlis, Giulia Magini, Roberta Rossi, Irinel Popescu, Laze Razvan, Stefan Schneeberger, Hans Blokzijl, Laura Llado, Miguel Angel Gomez Bravo, Christophe Duvoux, Vladimír Mezjlík, Gabriel C Oniscu, Kelsey Pearson, Murat Dayangac, Valerio Lucidi, Olivier Detry, Fernando Rotellar, Caroline den Hoed, Wojciech G Polak, Sarwa Darwish Murad
BACKGROUND AND AIMS: Management of Budd-Chiari Syndrome (BCS) has improved over the last decades. The main aim was to evaluate the contemporary post-liver transplant (LT) outcomes in Europe. APPROACH AND RESULTS: Data from all transplanted patients from 1976-2020 was obtained from the European Liver Transplantation Registry (ELTR). Patients<16yrs, with secondary BCS or hepatocellular carcinoma were excluded. Patient- (PS) and graft survival (GS) before and after 2000 were compared...
February 15, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
#12
REVIEW
Kanglian Zheng, Xiaodong Wang
Primary hepatobiliary cancers (PHCs), which mainly include hepatocellular carcinoma (HCC) and biliary tract cancers (BTCs), are mostly diagnosed in the advanced stage and are not candidates for curative surgery or ablation, resulting in a dismal prognosis. Targeted therapies with or without programmed death receptor 1 (PD-1)/PD-L1 inhibitors have been incorporated into first-line treatments for advanced HCC. Systemic chemotherapy is still the mainstay treatment for advanced BTCs, and combining it with PD-1/PD-L1 inhibitors has resulted in prolonged patient survival...
2024: Therapeutic Advances in Medical Oncology
#13
JOURNAL ARTICLE
Mohamed Yousry Taher, Ehab Mostafa Hassouna, Abeer Shawky El-Hadidi, Omar Sameh El-Aassar, Mohamed Fathy Bakosh
PURPOSE: Cytokeratin 19 fragment 21-1 (CYFRA 21-1) and cytokeratin 19 fragment 2G2 (CK 19-2G2) are two soluble fragments of cytokeratin 19 (CK 19) that can be detected in serum. CK 19-positive hepatocellular carcinoma (HCC) is characterized by an aggressive behavior and a poor outcome. This study aimed to assess the prognostic value of serum CYFRA 21-1 and CK 19-2G2 in predicting tumor aggressiveness and overall survival (OS) in patients with hepatic C virus (HCV)-related HCC. METHODS: The current study included 138 patients with HCV-related HCC recruited from the Hepatobiliary and Interventional Radiology Units at Alexandria's main university hospitals and 40 healthy individuals as controls...
January 17, 2024: Journal of Gastrointestinal Cancer
#14
JOURNAL ARTICLE
Xing Wang, Jin-Ni Luo, Xiao-Ying Wu, Qi-Xian Zhang, Bin Wu
BACKGROUND: Liver cirrhosis (LC) is a prevalent and severe disease in China. The burden of LC is changing with widespread vaccination of hepatitis B virus (HBV) and antiviral therapy. However, the recent transition in etiologies and clinical features of LC cases requiring hospitalization is unclear. AIM: To identify the transition in etiologies and clinical characteristics of hospitalized LC patients in Southern China. METHODS: In this retrospective, cross-sectional study we included LC inpatients admitted between January 2001 and December 2020...
December 27, 2023: World Journal of Hepatology
#15
RANDOMIZED CONTROLLED TRIAL
Etienne Garin, Lambros Tselikas, Boris Guiu, Julia Chalaye, Yan Rolland, Thierry de Baere, Eric Assenat, Vania Tacher, Xavier Palard, Desirée Déandreis, Denis Mariano-Goulart, Giuliana Amaddeo, Karim Boudjema, Antoine Hollebecque, Mohamad Azhar Meerun, Helen Regnault, Eric Vibert, Boris Campillo-Gimenez, Julien Edeline
Interim analysis of the DOSISPHERE-01 study demonstrated a strong improvement in response and overall survival (OS) on using 90 Y-loaded glass microspheres with personalized dosimetry compared with standard dosimetry in patients with nonoperable locally advanced hepatocellular carcinoma. This report sought to provide a long-term analysis of OS. Methods: In this phase II study (ClinicalTrials.gov identifier NCT02582034), treatment was randomly assigned (1:1) with the goal to deliver either at least 205 Gy (if possible >250-300 Gy) to the index lesion in the personalized dosimetry approach (PDA) or 120 ± 20 Gy to the treated volume in the standard dosimetry approach (SDA)...
February 1, 2024: Journal of Nuclear Medicine
#16
JOURNAL ARTICLE
Khai Viet Ninh, Dang Hai Do, Trung Duc Nguyen, Phuong Ha Tran, Tuan Hoang, Dung Thanh Le, Nghia Quang Nguyen
BACKGROUNDS/AIMS: Liver transplantation (LT) provides a favorable outcome for patients with hepatocellular carcinoma (HCC) and was launched in Vietnam in 2004. In this study, we evaluated the short-term and long-term outcomes of LT and its risk factors. METHODS: This retrospective study analyzed HCC patients who underwent LT at Viet Duc University hospital, Vietnam, from 01/2012-03/2022. The following data were gathered: demographics, virus infection, tumor characteristics, alpha-fetoprotein (AFP) level, Child-Pugh and MELD scores, selection criteria, type of LT, complications, 30-day mortality, and disease-free and overall survival (DFS and OS)...
January 9, 2024: Annals of Hepato-Biliary-Pancreatic Surgery
#17
JOURNAL ARTICLE
Xiao Cheng, Yujun Tang, Qinjun He, Jiankang Song, Kunyuan Wang, Hui Li, Jing Huang, Weibin Wang, Junying Li, Haiyu Wang, Minghan Tu, Jinzhang Chen, Guosheng Yuan, Shuai Kang, Hongyan Liu, Xiaoyong Zhang, Wenfan Luo, Yali Ji, Xiaoqin Lan, Ling Zhou, Qintao Lai, Xiaoqin Luo, Qiaoping Wu, Damei Zhou, Yingqi Tan, Jinjun Chen, Xiaofeng Zhang
BACKGROUND: Esophagogastroduodenoscopy (EGD) is required to screen for high-risk varices (HRV) in patients with hepatocellular carcinoma (HCC), especially since overall survival rates have dramatically improved with new systemic therapies. AIM: To assess the Baveno VI and Baveno VII algorithms' ability to rule out HRV in hepatitis B virus (HBV)-related HCC METHODS: We prospectively enrolled consecutive patients with HBV related, compensated cirrhosis and newly diagnosed HCC who underwent liver stiffness measurement, spleen stiffness measurement (SSM) using a 100-Hz shear wave frequency, and EGD...
December 28, 2023: Alimentary Pharmacology & Therapeutics
#18
JOURNAL ARTICLE
Zhipeng Lin, Du Chen, Xiaolong Hu, Dabei Huang, Yuan Chen, Jian Zhang, Xiaoqun Li, Xugong Zou
This study aimed to evaluate the clinical efficacy of hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib and PD1 inhibitors vs. transarterial chemoembolization (TACE) combined with lenvatinib and PD1 inhibitors in the treatment of unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) and artery-portal shunts (APFs). HCC Patients with PVTT and APFs who received HAIC in combination with PD1 inhibitor or TACE in combination with lenvatinib and PD1 inhibitor from March 2019 to May 2023 in Zhongshan People's Hospital were included...
2023: American Journal of Cancer Research
#19
REVIEW
Yixin Ding, Shasha Wang, Zhenkang Qiu, Chunyang Zhu, Yan Wang, Shufen Zhao, Wensheng Qiu, Kongjia Wang, Jing Lv, Weiwei Qi
Systemic therapy remains the primary therapeutic approach for advanced hepatocellular carcinoma (HCC). Nonetheless, its efficacy in achieving control of intrahepatic lesions is constrained. Hepatic arterial infusion chemotherapy (HAIC) is a therapeutic approach that combines localized treatment with systemic antitumor effects, which aim is to effectively manage the progression of cancerous lesions within the liver, particularly in patients with portal vein tumor thrombosis (PVTT). Combining HAIC with anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb) immunotherapy is anticipated to emerge as a novel therapeutic approach aimed at augmenting the response inside the localized tumor site and achieving prolonged survival advantages...
2023: Frontiers in Immunology
#20
JOURNAL ARTICLE
Xinqiang Han, Peng Zhao, Xuemin Wang, Xiaoyu Tan, Yongzhen Zhang
OBJECTIVES: To investigate the safety and feasibility of subcutaneous implantable infusion ports in repeated hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma (HCC) in China. METHODS: A total of 237 patients who were clinically diagnosed with advanced HCC (CNLC III a/III b) in our hospitals from December 2020 to October 2022 were retrospectively analyzed. The approaches of HAIC were divided into 2 groups: arterial infusion port implantation (group A) and one-time femoral artery catheterization (group B) based on the physicians' suggestion and the patients' intention...
December 2023: Saudi Medical Journal
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
